Toi M, Tominaga T, Osaki A, Toge T
Dept. of Surgery, Tokyo Metropolitan Komagome Hospital, Japan.
Breast Cancer Res Treat. 1994 Jan;29(1):51-8. doi: 10.1007/BF00666181.
We have conducted two series of studies, a biochemical study and an immunocytochemical study, to investigate the role of epidermal growth factor receptor (EGFR) expression in primary breast cancer patients. In the biochemical study, a consecutive 115 patients were included and EGFR was measured by a competitive binding assay with multipoint Scatchard analysis. In the immunocytochemical study comprising 126 patients, EGFR status was determined by immunostaining with anti-EGFR antibody EGFR1. Several agreements were found from these two studies. EGFR status was inversely correlated with estrogen receptor (ER) status. No significant correlation was found between EGFR status and tumor size, nodal metastases, or the expression of c-erbB-2 protein. Ki-67 immunoreactivity, a cellular proliferation marker, was enhanced in EGFR positive tumors over EGFR negative tumors, suggesting a linkage of EGFR expression to cellular proliferative activity. Post-operative follow up showed that relapse-free survival for EGFR positive patients was significantly worse than that for EGFR negative patients, particularly in node-positive patients. Multivariate analysis demonstrated a significance of EGFR status as an independent prognostic indicator in primary breast cancer. The group expressing EGFR and c-erbB-2 protein indicated a particularly high risk for relapse.
我们开展了两项系列研究，一项生化研究和一项免疫细胞化学研究，以调查表皮生长因子受体（EGFR）表达在原发性乳腺癌患者中的作用。在生化研究中，纳入了连续的115例患者，并通过多点Scatchard分析的竞争性结合试验来检测EGFR。在包含126例患者的免疫细胞化学研究中，通过用抗EGFR抗体EGFR1进行免疫染色来确定EGFR状态。从这两项研究中发现了一些一致性结果。EGFR状态与雌激素受体（ER）状态呈负相关。EGFR状态与肿瘤大小、淋巴结转移或c-erbB-2蛋白表达之间未发现显著相关性。细胞增殖标志物Ki-67免疫反应性在EGFR阳性肿瘤中比EGFR阴性肿瘤中增强，提示EGFR表达与细胞增殖活性之间存在联系。术后随访显示，EGFR阳性患者的无复发生存期明显比EGFR阴性患者差，尤其是在淋巴结阳性患者中。多变量分析表明，EGFR状态作为原发性乳腺癌的独立预后指标具有重要意义。同时表达EGFR和c-erbB-2蛋白的组显示出特别高的复发风险。
